•A late-stage trial of Imfinzi, combined with a targeted therapy prior to surgery, showed significantly improved survival rates in patients with muscle-invasive bladder cancer.
•BIMIZCI filed a definitive proxy statement to nominate three independent directors to the Medallion Financial board for the annual meeting on June 9, 2026.
•BIMIZCI cites deteriorating financial performance, with 1Q26 earnings at their lowest since 2020 and consumer loan charge-offs at 15-year highs.
•BIMIZCI raised governance concerns, including a $4.6 million bonus for the CEO despite a 2025 federal court injunction for securities law violations.